Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Clinical trial NCT00530348 · COMPLETED

Trial details

NCT number: NCT00530348
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2007-08-01
Primary completion: 2011-04-01
Enrollment: 581

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.